On September 16, 2026, Halozyme Therapeutics announced a proposed offering of $1.05 billion in aggregate principal amount of convertible senior notes due 2033, with an option to increase the size by up to $150 million. The company intends to use net proceeds to fund capped call transactions and repurchase its existing 0.25% convertible notes due 2027 and 1.00% convertible notes due 2028 through privately negotiated transactions, with remaining funds allocated for general corporate purposes including working capital and potential acquisitions. Halozyme Therapeutics is a biopharmaceutical company specializing in drug delivery technologies, including the ENHANZE platform and auto-injector products.
